Phastar
Dr. Jennifer Bradford is leading Phastar’s data science group, which is applying artificial intelligence (AI) and machine learning (ML) to ‘maximize the value of clinical trial data.’
According to the global contract research organization (CRO), the new team complements its existing offerings and will enable the ‘best use’ of data and metadata.
After completing her post-doc studies at the University of Manchester, she joined the advanced analytics group at AstraZeneca, before taking a role at Cancer Research UK.
"The advancement of technologies such as AI and machine learning are rapidly modernizing clinical trials and improving their efficacy,” said Bradford.
“Phastar already employs robust statistics and data analysis methods – leading our professional data science group, I am looking forward to guiding our biotech, pharma, and medical device customers to see the business possibilities in this new era," she told us.